(4-aminophenyl)-(4aRS,8aSR)-octahydroquinolin-1-ylmethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (4-aminophenyl)-(4aRS,8aSR)-octahydroquinolin-1-ylmethanone
• 英文别名: (4-aminophenyl)-(4aS*,8aR*)-octahydro-1(2H)-quinolln-1-yl-methanone；(4-aminophenyl)-(4aS*,8aR*)-octahydro-1(2H)-quinolin-1-yl-methanone；[(4aS,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-1-yl]-(4-aminophenyl)methanone
• 化学式: C₁₆H₂₂N₂O
• 分子量: 258.363
• InChiKey: SUWUPXQKMXNZPS-SWLSCSKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-aminophenyl)-(4aRS,8aSR)-octahydroquinolin-1-ylmethanone 在 sodium hydroxide 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 N-[4-((4aRS,8aSR)-octahydroquinoline-1-carbonyl)phenyl]terephthalamic acid
  参考文献：
  名称：

  Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1

  摘要：

  High-throughput screening identified 5 as a weak inhibitor of 11 beta-HSD1. Optimization of the structure led to a series of perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A tertiary benzamide is required for biological activity and substitution of the terminal benzamide with either electron-donating or -withdrawing groups is tolerated. The majority of the compounds show selectivity of > 20 to > 700-fold over 11 beta-HSD2. Analogues which showed >50% inhibition of 11 beta-HSD1 at 1 mu M in an cellular assay were screened in an ADX mouse model. A maximal response of > 70% reduction of liver corticosterone levels was observed for three compounds; 9m, 25 and 49.

  DOI：

  10.1021/jm058228q
• 作为产物：
  描述：

  (4-nitrophenyl)-(4aRS,8aSR)-octahydroquinolin-1-ylmethanone 在 钯 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以to give (4-aminophenyl)-(4aS*,8aR*)-octahydro-1(2H)-quinolin-1-yl-methanone的产率得到(4-aminophenyl)-(4aRS,8aSR)-octahydroquinolin-1-ylmethanone
  参考文献：
  名称：

  Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I

  摘要：

  化合物(I)的配方提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏中的糖皮质激素浓度，特别是人类肝脏中的皮质醇浓度，从而抑制了肝糖异生并降低了血浆葡萄糖水平。因此，本发明的化合物在哺乳动物中可能特别有用作为降糖药物，用于治疗和预防与高血糖和/或胰岛素抵抗有关的疾病，例如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，例如综合征X、血脂异常、高血压和中心性肥胖。此外，本发明还涉及使用根据本发明的化合物制备药物，特别是用于改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，并通过降低糖皮质激素浓度来降低肝糖异生的药物，用于治疗和预防糖皮质激素相关疾病。

  公开号：

  US20060205772A1

文献信息

• [EN] AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] DERIVES AMIDO ET LEUR UTILISATION COMME INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 1
  申请人：NOVARTIS AG

  公开号：WO2004065351A1

  公开（公告）日：2004-08-05

  Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.

  化合物的化学式（I）提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏内的糖皮质激素浓度，特别是降低了人类肝脏内的皮质醇浓度，从而抑制了肝葡萄糖生成和降低了血浆葡萄糖水平。因此，本发明的化合物可能特别适用于哺乳动物作为降糖药物，用于治疗和预防高血糖和/或胰岛素抵抗等疾病，如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，如X综合症、血脂异常、高血压和中心性肥胖。此外，本发明还涉及根据本发明的化合物用于制备药物，特别是用于治疗和预防与糖皮质激素相关疾病的药物，通过改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，以及减少内脏脂肪组织形成。
• Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I
  申请人：Coppola Mark Gary

  公开号：US20060205772A1

  公开（公告）日：2006-09-14

  Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing

  化合物(I)的配方提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏中的糖皮质激素浓度，特别是人类肝脏中的皮质醇浓度，从而抑制了肝糖异生并降低了血浆葡萄糖水平。因此，本发明的化合物在哺乳动物中可能特别有用作为降糖药物，用于治疗和预防与高血糖和/或胰岛素抵抗有关的疾病，例如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，例如综合征X、血脂异常、高血压和中心性肥胖。此外，本发明还涉及使用根据本发明的化合物制备药物，特别是用于改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，并通过降低糖皮质激素浓度来降低肝糖异生的药物，用于治疗和预防糖皮质激素相关疾病。
• AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Novartis AG

  公开号：EP1590319A1

  公开（公告）日：2005-11-02
• Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1
  作者：Gary M. Coppola、Paivi J. Kukkola、James L. Stanton、Alan D. Neubert、Nicholas Marcopulos、Natalie A. Bilci、Hua Wang、Hollis C. Tomaselli、Jenny Tan、Thomas D. Aicher、Douglas C. Knorr、Arco Y. Jeng、Beatriz Dardik、Ricardo E. Chatelain

  DOI：10.1021/jm058228q

  日期：2005.10.1

  High-throughput screening identified 5 as a weak inhibitor of 11 beta-HSD1. Optimization of the structure led to a series of perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A tertiary benzamide is required for biological activity and substitution of the terminal benzamide with either electron-donating or -withdrawing groups is tolerated. The majority of the compounds show selectivity of > 20 to > 700-fold over 11 beta-HSD2. Analogues which showed >50% inhibition of 11 beta-HSD1 at 1 mu M in an cellular assay were screened in an ADX mouse model. A maximal response of > 70% reduction of liver corticosterone levels was observed for three compounds; 9m, 25 and 49.